Here are five observations:
1. The clinical trial, which is testing the company’s allogeneic bone forming cell product, exhibited no safety concerns. The trial tests the safety and efficacy of the treatment over a 12-month period.
2. The Phase IIA study will test 16 patients with symptomatic degenerative lumbar disc disease who need interbody fusion surgery.
3. The clinical trial involves an interbody cage supplemented with ALLOB and bioceramic granules.
4. The trial, occurring in eight Belgium centers, involves one more group of four patients.
5. “We are pleased to see consistent safety being reported with our allogeneic bone cell therapy product,” said Enrico Bastianelli, CEO, Bone Therapeutics. “Recruitment for the spinal fusion trial is progressing quickly and is now 75 percent complete.”
More articles on spine:
8 key notes on pediatric cervical spinal cord injury
Lumbar fusion’s impact on healthcare resource utilization: 5 things to know
Dr. Jonathan Russin runs LA marathon with former patient — 5 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.